Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.
Overview
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients is a phase 1/2 interventional study registered as NCT05222555 by Incyte Corporation, with 53 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2024-07-17. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
Shares Tafasitamab, Incyte, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialL-MIND
Shares Tafasitamab, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialTo Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL
Shares Tafasitamab, Incyte, Lenalidomide, Diffuse large B-cell lymphoma.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Tafasitamab, Incyte, Lenalidomide.
- TrialExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Shares Tafasitamab, Incyte.
- TrialfrontMIND
Shares Tafasitamab, Lenalidomide, Diffuse large B-cell lymphoma.
- CompanyMorphoSys (Novartis)
Shares Tafasitamab, Diffuse large B-cell lymphoma.
- TrialBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL